厄洛替尼联合NP方案治疗非小细胞肺癌的临床疗效分析  

An Analysis of the Clinical Effects of Erlotinib Combined with NP Regiment in the Treatment of Non-cell Lung Cancer

作　　者：周丽华[1] 刘胜岗[1] 杨红忠[1] 彭毅强[1] 聂华萍[1] 梁伟军[1] 周辉[2] 

机构地区：[1]长沙市中心医院,湖南长沙410004 [2]中南大学湘雅医学院附属肿瘤医院胸一科,湖南长沙410013

出　　处：《肿瘤药学》2014年第2期126-130,共5页Anti-Tumor Pharmacy

基　　金：湖南省科技厅科技计划项目资助(2012SK3249)

摘　　要：目的观察厄洛替尼联合NP方案治疗非小细胞肺癌的临床效果和安全性。方法将2012年3月至2012年12月在我院治疗的45例非小细胞肺癌患者随机分为两组,对照组接受NP方案治疗,治疗组接受厄洛替尼联合NP方案治疗,至少治疗2个周期后评价两组患者的临床疗效及不良反应。结果治疗组和对照组的疾病有效率(RR)分别为56.5%和45.5%,两组比较差异无统计学意义(P>0.05);治疗组和对照组的疾病控制率(DCR)分别为82.6%和68.2%,治疗组显著高于对照组,差异有统计学意义(P<0.05);治疗组和对照组的生活质量改善率分别为60.9%和40.9%,治疗组显著高于对照组,差异有统计学意义(P<0.05);治疗组胃肠道反应、脱发以及皮疹的发生率显著低于对照组(P<0.05),而两组血细胞减少、疲乏以及周围神经炎的发生率差异无统计学意义(P>0.05)。结论厄洛替尼联合NP方案治疗非小细胞肺癌能显著提高患者的疾病控制率和生活质量,减少化疗所致的毒副反应,值得在临床推广应用。Objective To investigate the clinical effects and safety of erlotinib combined with NP regimen in the treatment of non-small cell lung cancer（NSCLC）. Methods Between March and December in 2012, 45 cases of NSCLC admitted in our oncology department were selected and divided into two groups randomly. The control group was treated with NP regimen while the treatment group was treated with erlotinib combined with NP regimen. The clinical efficacy and incidence of adverse reac-tions were compared after at least two treatment cycles. Results The response rate （RR） in treating group and control group were respectively 56.5%and 45.5%（P〉0.05）;the desease control rate （DCR） of treating group was 82.6%, significantly higher than that of the control group（68.2%）（P〈0.05）;the improvement rate of KPS of treating group was 60.9%, also significantly higher than that of the control group（40.9%）（P〈0.05）. The incidence rates of gastrointestinal reaction, hair loss and skin rash of treat-ing group was statistically lower than that of the control group（P〈0.05）. However, there were no statistical differences in the incidence rates of hypocytosis, fatigue, peripheral neuritis between the two groups（P〉0.05）. Conclusion Erlotinib combined with NP regimen could significantly improve the quality of life, lessen the side effects caused by chemotherapy in the treatment of NSCLC. It was worth promoting in clinic.

关 键 词：厄洛替尼 NP方案 非小细胞肺癌 临床疗效 

分 类 号：R734.2[医药卫生—肿瘤]